___

• 1. Çalışkan E, Çakıroğlu Y. Kontrollü over hiperstimülasyonu protokolleri. Yardımcı Üreme Teknikleri (Editör: Önder Çelik). Adana. Nobel Kitabevi (Özyurt Matbaacılık). 2011;271-314.
• 2. Carmel PW, Araki S, Ferin M. Pituitary stalk portal blood collection in rhesus monkeys: evidence for pulsatile release of gonadotropin-releasing hormone (GnRH). Endocrinology. 1976;99(1):243-8.
• 3. Özeren M. Kontrollü over uyarısı için kullanılan ilaçlar: klomifen sitrat, aromataz inhibitörleri, gonadotropinler ve gonadotropin serbestleştirici hormon analogları. Yardımla Üreme Teknikleri Temel Kitabı (Çeviri editörleri: Tülay Erez, Oktay Arda, Semih Kaleli). İstanbul. Nobel tıp kitabevleri (Nobel matbaacılık). 2010;519-39.
• 4. Bäckström CT, McNeilly AS, Leask RM, Baird DT. Pulsatile secretion of LH, FSH, prolactin, oestradiol and progesterone during the human menstrual cycle. Clin Endocrinol (Oxf). 1982;17(1):29-42.
• 5. Reame N, Sauder SE, Kelch RP, Marshall JC. Pulsatile gonadotropin secretion during the human menstrual cycle: evidence for altered frequency of gonadotropin-releasing hormonesecretion. J Clin Endocrinol Metab. 1984;59(2):328-37.
• 6. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 1980;36:53-88.
• 7. Knobil E, Hotchkiss J. The menstruel cycle and its neuroendocrine control. In: Knobil E, Neill J, eds. The Physiology of Reproduction. New York: Raven Press, 1988.
• 8. Lemay A, Maheux R, Faure N, Jean C, Fazekas AT. Reversible hypogonadism induced by a luteinizing hormonereleasing hormone (LH-RH) agonist (Buserelin) as a new therapeuticapproach for endometriosis. Fertil Steril. 1984;41(6):863-71.
• 9. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995;10(8):1974-81.
• 10. Fleming R, Coutts JR. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil Steril. 1986;45(2):226-30.
• 11. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, Schoemaker J. Dosefinding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod. 2000;15(11):2333-40.
• 12. Loumaye E. The control of endogenous secretion of LH by gonadotrophin releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod. 1990;5(4):357-76.
• 13. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmüller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788-91.
• 14. Felberbaum RE, Albano C, Ludwig M, Riethmüller-Winzen H, Grigat M, Devroey P, Diedrich K. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod. 2000;15(5):1015-20.
• 15. Fluker M1, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB; North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75(1):38-45.
• 16. Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol 2012;10:26.
• 17. Albuquerque LE, Tso LO, Saconato H, Albuquerque MC, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;1:CD002808.
• 18. van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril. 2003;80(5):1086-93.
• 19. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310-5.